HC Wainwright Boosts AngioDynamics (NASDAQ:ANGO) Price Target to $15.00

AngioDynamics (NASDAQ:ANGO - Free Report) had its price target increased by HC Wainwright from $14.00 to $15.00 in a research report report published on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the medical instruments supplier's stock.

Separately, Canaccord Genuity Group reduced their target price on AngioDynamics from $13.00 to $12.00 and set a "buy" rating on the stock in a report on Friday, October 4th.

AngioDynamics Stock Down 4.9 %

NASDAQ ANGO traded down $0.64 during trading hours on Friday, hitting $12.30. The company's stock had a trading volume of 2,225,146 shares, compared to its average volume of 1,480,073. AngioDynamics has a twelve month low of $5.26 and a twelve month high of $13.13. The firm has a market capitalization of $499.80 million, a P/E ratio of -2.02 and a beta of 0.59. The stock has a fifty day moving average of $8.23 and a 200 day moving average of $7.42.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last posted its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.07. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $72.90 million for the quarter, compared to the consensus estimate of $70.93 million. During the same quarter in the prior year, the business posted ($0.05) EPS. The firm's quarterly revenue was down .1% on a year-over-year basis. On average, analysts predict that AngioDynamics will post -0.41 earnings per share for the current year.

Hedge Funds Weigh In On AngioDynamics

Several institutional investors and hedge funds have recently made changes to their positions in ANGO. Bank of New York Mellon Corp lifted its holdings in AngioDynamics by 9.7% during the second quarter. Bank of New York Mellon Corp now owns 174,742 shares of the medical instruments supplier's stock worth $1,057,000 after acquiring an additional 15,412 shares in the last quarter. First Eagle Investment Management LLC acquired a new stake in shares of AngioDynamics during the second quarter worth about $1,321,000. AE Wealth Management LLC bought a new position in shares of AngioDynamics during the 2nd quarter valued at about $87,000. Cubist Systematic Strategies LLC grew its position in shares of AngioDynamics by 15.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 226,503 shares of the medical instruments supplier's stock valued at $1,370,000 after purchasing an additional 29,669 shares during the period. Finally, Deerfield Management Company L.P. Series C increased its stake in AngioDynamics by 135.1% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 109,536 shares of the medical instruments supplier's stock worth $663,000 after purchasing an additional 62,945 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.